Determination of 5-Methyltetrahydrofolate (13C-Labeled and Unlabeled) in Human Plasma and Urine by Combined Liquid Chromatography Mass Spectrometry
β Scribed by David J. Hart; Paul M. Finglas; Caroline A. Wolfe; Fred Mellon; Anthony J.A. Wright; Susan Southon
- Publisher
- Elsevier Science
- Year
- 2002
- Tongue
- English
- Weight
- 106 KB
- Volume
- 305
- Category
- Article
- ISSN
- 0003-2697
No coin nor oath required. For personal study only.
β¦ Synopsis
The association of folates with the prevention of neural tube defects and reduced risk of other chronic diseases has stimulated interest in the development of techniques for the study of their bioavailability in humans. Stable isotope protocols differentiate between oral and/or intravenous test doses of folate and natural levels of folate already present in the body. An liquid chromatography/mass spectrometry (LC/MS) procedure is described that has been validated for the determination of [ 13 C]5-methyltetrahydropteroyl monoglutamic acid ([ 13 C]5-CH 3 H 4 PteGlu) in plasma and urine, following oral dosing of volunteers with different labeled folates. Folate binding protein affinity columns were used for sample purification prior to LC/MS determination. Chromatographic separation was achieved using a Superspher 100RP18 (4 m) column and mobile phase of 0.1 mol/L acetic acid (pH 3.3):acetonitrile (90:10; 250 L/min). Selected ion monitoring was conducted on the [M-H] Ψ ion: m/z 458 and 459 for analyzing 5-CH 3 H 4 PteGlu; m/z 464 [MΨ6-H] Ψ to determine 5-CH 3 H 4 PteGlu derived from the label dose; m/z 444 for analysis of 2 H 4 PteGlu internal standard, and m/z 446 and 478 to confirm that there was no direct absorption of unmetabolized compounds. Calibration was linear over the range 0 -9 Ψ 10 Ψ9 mol/L; the limits of detection and quantification were 0.2 Ψ 10 Ψ9 and 0.55 Ψ 10 Ψ9 mol/L, respectively. The mean coefficient of variation of the ratios (m/z 463/458) was 7.4%. The method has potential applications for other key folates involved in one-carbon metabolism.
π SIMILAR VOLUMES
## Abstract BMSβ378806 is a human immunodeficiency virus (HIV) entry inhibitor that is being developed for the oral treatment of HIV infection. Human plasma and urine LC/MS/MS methods have been developed and validated for the quantitation of BMSβ378806. For human plasma method, methyl __t__βbutyl e
A liquid chromatographic/tandem mass spectrometric (LC/MS/MS) assay was developed for the quantitative determination of olanzapine (LY170053, OLZ) in human plasma and serum. Bond Elut solid-phase extraction C 2 cartridges (single cartridge or 96-well format), in conjunction with a positive pressure
Rapid, sensitive and selective methods were developed for the determination of dextromethorphan and its major metabolite, dextrorphan, in human plasma using liquid chromatography/tandem mass spectrometry (LC/MS/MS). Plasma samples spiked with stable-isotope internal standards were prepared for analy